Archive · 24 Nov 2025
UBS Predicts 60% Upside for Shaily Engineering
UBS, a big investment company, thinks Shaily Engineering, a company that makes special plastic parts, is a great investment.
They say the company's stock could go up by 60% because it has special technology for making medicine pens.
These pens are in high demand, especially after a big medicine patent expires in 2026.
UBS believes Shaily can make a lot of money from this.
The company's stock has already gone up a lot in the past few years, making it a big winner for investors.
UBS also thinks the company could get even more business from other areas like electronics and semiconductors.
All these reasons make UBS very optimistic about Shaily Engineering's future.
UBS initiated coverage on Shaily Engineering with a 'Buy' rating and a target price of ₹4,000, predicting a 60% upside.
Shaily Engineering has patented technology for fixed-dose and auto-injector pens, positioning it well for the launch of generic GLP-1 therapies.
The GLP-1 patent is set to expire in 2026 in key markets, representing a total addressable market of 550–600 million devices.
UBS forecasts a 96% revenue CAGR for Shaily's healthcare segment between FY25 and FY28E, up from the current ₹1.6 billion.
Shaily Engineering's stock has surged 700% over the past two years, making it one of the biggest wealth creators in the Indian equity market.
- Who
- UBS, Shaily Engineering Plastics
- What
- UBS initiated coverage on Shaily Engineering with a 'Buy' rating and a target price of ₹4,000, predicting a 60% upside.
- When
- The GLP-1 patent is set to expire in 2026 in key markets.
- Where
- Key markets include India, Canada, and Brazil.
- Why
- Shaily's patented technology and strong market position in the healthcare segment.
- Company
- Shaily Engineering Plastics
- Brokerage Firm
- UBS
- Rating
- Buy
- Target Price
- ₹4,000
- Upside Potential
- 60%
- Patented Technology
- Fixed-dose and auto-injector pens
- GLP-1 Patent Expiry
- 2026 in key markets
- Revenue Forecast
- ₹80–85 billion by 2030
- Revenue CAGR (FY25-FY28E)
- 96%
- EPS CAGR (FY25–28)
- 75%
- Stock Performance (2 Years)
- 700%
- Stock Performance (10 Years)
- 7042%
- Stock Performance (11 Years)
- 25410%
- Current Year Gains
- 73%